Research Archive — Page 73 of 133

From left, Kimryn Rathmell, MD, PhD, Bradley Reinfeld, Matthew Madden and Jeffrey Rathmell, PhD, have discovered that immune cells — not cancer cells — are the major glucose consumers in the tumor microenvironment, upending a century-old observation.
April 7, 2021

Study revises understanding of cancer metabolism

Tumors consume glucose at high rates, but a team of Vanderbilt researchers has discovered that cancer cells themselves are not the culprit, upending models of cancer metabolism that have been developed and refined over the last 100 years.

By Leigh MacMillan
April 1, 2021

COVID-19 met with intensive teamwork

Team members serving COVID-19 inpatients were more densely connected, interacting far more than their medical ICU counterparts.

By Paul Govern
April 1, 2021

Novel way to neutralize Rift Valley Fever Virus

The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development.

By Bill Snyder
Deanna Edwards, PhD, left, Jin Chen, MD, PhD, and colleagues are studying a new therapeutic strategy for triple-negative breast cancer.
April 1, 2021

Breast cancer cells ‘steal’ nutrients from immune cells: study

Triple-negative breast cancer cells engage in a “glutamine steal” — outcompeting T cells for the nutrient glutamine and impairing their ability to kill tumor cells, Vanderbilt researchers have discovered.

By Leigh MacMillan
April 1, 2021

Study shows new COVID target could improve vaccines

Despite an impressive vaccination effort that exceeds 2 million shots a day, rates of COVID-19 are again on the rise in several parts of the United States, as is the spread of highly transmissible variants of the virus.

By Bill Snyder
March 25, 2021

Forty-three percent of melanoma patients have chronic complications from immunotherapies

Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.

By Tom Wilemon